Conference Correspondent

News, views, and coverage of important topics and discussions from oncology conferences and events.

2020
- ASCO 2020 - Lung Cancer
2019
- ASH 2019 - CLL
- ASCO 2019 - CLL
2018
- ASH 2018 CLL
- ID Week 2018
2017
2016
- ASH 2016 - Chronic Lymphocytic Leukemia
- ASH 2016 - Multiple Myeloma

Dual Inhibition of Bruton’s Tyrosine Kinase and BCL2: A Promising Therapeutic Strategy for Myeloid and Lymphoid Leukemias

Ibrutinib 7-Year Follow-Up Data in First-Line and Relapsed/Refractory Patients with CLL/SLL

Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk CLL

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of Patients with CLL with Mutated IGHV

Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression-Free Survival Compared with Bendamustine plus Rituximab in Untreated Older Patients with CLL

Results from the Phase 3 iLLUMINATE Study: Ibrutinib + Obinutuzumab as First-Line Treatment in Patients with CLL/SLL

Acalabrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia: Updated Results from the Phase 1/2 ACE-CL-001 Study

Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed/Refractory CLL

MURANO Study: The Impact of Minimal Residual Disease on Long-Term Clinical Outcomes After Venetoclax plus Rituximab

CLL Treatment Patterns, Dosing, and Sequencing: Interim Analysis Results from the Prospective informCLL Real-World Registry

4
5
6
7
8
9
10

Page 7 of 25
Results 61 - 70 of 242

SUBSCRIBE

© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

AHDB Print Edition

AHDB Weekly e‑Newsletter

I have reviewed and consent to the terms of AHDB's Privacy Policy, and AHDB has my permission to retain my information in its database, and to forward pertinent communications to me.